Inegy

Simvastatin/Ezetimibe, the active ingredient in Inegy, is a statin and cholesterol absorption inhibitor presented as a tablet for oral use. It lowers elevated cholesterol levels in adults with hypercholesterolemia, mixed dyslipidemia, or familial hypercholesterolemia, helping reduce cardiovascular risk.

GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality for global lipid‑lowering therapy programs. The company adheres to stringent manufacturing standards and offers flexible packaging options to meet diverse market requirements.

Inegy combines simvastatin and ezetimibe to treat lipid disorders by lowering cholesterol levels.

Hypercholesterolemia: reduces low‑density lipoprotein cholesterol (LDL‑C) in patients with primary hypercholesterolemia. Mixed dyslipidemia: improves overall lipid profile by decreasing LDL‑C and triglycerides while modestly raising HDL‑C. Familial hypercholesterolemia: provides additional LDL‑C reduction in individuals with genetically elevated cholesterol.

Inegy may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Myalgia (muscle pain) - Elevated liver enzymes (ALT, AST) - Diarrhea - Headache

Serious or Rare Side Effects: - Rhabdomyolysis (muscle breakdown) - Severe hepatic injury - Acute renal failure - Anaphylactic reactions

Before prescribing Inegy, consider the following precautions.

Assess liver function: obtain baseline hepatic enzymes before initiating therapy. Monitor muscle symptoms: educate patients to report unexplained muscle pain or weakness. Avoid use in active liver disease: contraindicated in patients with persistent transaminase elevations. Caution in renal impairment: dose adjustment may be required in severe renal dysfunction. Drug interactions: review concomitant medications that affect statin metabolism. Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Inegy can interact with several medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may markedly increase simvastatin exposure and risk of rhabdomyolysis. - Gemfibrozil: synergistic increase in muscle toxicity. - Cyclosporine: elevates both simvastatin and ezetimibe levels, raising risk of hepatic and muscular adverse events.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Niacin: combined use can increase risk of liver enzyme elevations. - Antacids containing aluminum/magnesium: may reduce ezetimibe absorption; separate dosing by at least 2 hours.